ImmunoGen (IMGN) Looks Good: Stock Adds 7.6% In Session

ImmunoGen, Inc. (NASDAQ:IMGN) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.27 to $4.62 in the past one-month time frame.

The move came after the company announced that the FDA has advised to conduct a new single-arm pivotal study, which can support accelerated approval for mirvetuximab soravtansine in ovarian cancer.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

ImmunoGen currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

ImmunoGen, Inc. Price

Investors interested in the Medical - Drugs industry may consider Jounce Therapeutics, Inc. (NASDAQ:JNCE) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is IMGN going up? Or down? Predict to see what others think:Up or Down

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>